Immunotherapy for a Cancer-Free Future
Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Our Approach
Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.
Meet our leadership team
Scancell has a bold ambition: to deliver and develop immunotherapies for a cancer free future. Our leadership team combines experienced and talented people who are committed to advancing our clinical programmes and translating innovative science for patient benefit.
LATEST NEWS
Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.